Lyra Therapeutics, Inc.
LYRA
$10.45
-$0.23-2.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 22.15% | 7.53% | 75.33% | -114.37% | -48.14% |
| Total Depreciation and Amortization | -15.23% | 287.18% | -73.10% | 6.62% | 60.00% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | -- | -- |
| Total Other Non-Cash Items | -50.66% | 53.39% | -95.67% | 1,947.84% | 211.93% |
| Change in Net Operating Assets | 43.17% | 59.92% | -303.15% | 297.15% | 68.77% |
| Cash from Operations | 22.11% | 30.03% | 18.81% | 11.02% | -17.82% |
| Capital Expenditure | -- | 213.73% | 73.98% | 90.88% | -173.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 242.69% | -77.48% | 263.50% | 736.51% |
| Cash from Investing | -- | 245.55% | -77.50% | 360.43% | 433.06% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -99.90% | -54.20% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 76.53% | 42.01% | 47.52% |
| Cash from Financing | -- | 95.65% | 74.16% | -101.03% | -54.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -152.70% | 307.01% | -150.32% | 370.51% | -138.45% |